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INTRODUCTION: Laparoscopic resection of locally advanced gastrointestinal stromal tumours (GISTs) is
rarely offered to patients as a ﬁrst line of treatment.
PRESENTATIONOF CASES:Wepresent two cases of locally advanced gastric GISTs successfully treatedwith
neoadjuvant imatinib and followed up by complete laparoscopic excision of the residual tumour mass.
There was no evidence of local recurrence or distant metastases after a mean follow up of more than 40
months.
DISCUSSION: Over the last decade, the development of imatinib has totally revolutionized management
of metastatic GISTs and it is now possible to achieve primary tumour downstaging of more than 80%.
Unfortunately, current literature on laparoscopic excision of locally advanced gastric GISTs following
neoadjuvant treatment of imatinib remains scarce. The present cases strongly suggest that this new
therapeutic approach might become the preferred medical option in such clinical situation.
CONCLUSION: Patients with locally advanced non-metastatic gastric GISTs should be offered ﬁrst-line
neoadjuvant. Imatinib-based cytoreductive chemotherapy as an alternative to radical debulking surgery,
as a substantial proportion of them will experience signiﬁcant tumour shrinkage and therefore beneﬁt
from a much less invasive laparoscopic approach.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gastrointestinal stromal tumours (GISTs) arise from the inter-
stitial cells of Cajal, specialized cells of the autonomic nervous
system located within the wall of the gastrointestinal tract and
responsible for paced contractions of the intestinal musculature
‘pacemakers’ as well as modulation of enteric neurotransmission
[1]. The most common location of GISTs is in the stomach and
accounts for around two-thirds of them, followed up by the small
intestine, colon and rectum, and rarely oesophagous or appendix
[2]. Diagnosis is histological and characterized by a high expres-
sion of a c-KIT proto-oncogene (CD117, tyrosine kinase receptor),
and CD34 on immunohistochemistry. The prediction ofmalignancy
remains difﬁcult and relies on a combination of several criteria that
includemitotic activity count, tumour size, presenceofnecrosis and
invasive growth [3].
Surgery is the treatment of choice of non-metastatic GISTswhen
a complete R0 resection (clear margins) can be achieved with low
morbidity, and routine lymphadenectomy is not required as those
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lesions rarely metastasize to the nearby lymph nodes [4]. With the
development of stapling devices, laparoscopic wedge resection of
small gastric lesionshasbecome thepreferred surgical techniqueas
it signiﬁcantly reduces post-operativepain andmorbidity, shortens
hospital length of stay, while maintaining adequate overall long-
term clinical outcome [5].
Recently published series have demonstrated similar results
with gastric GISTs larger than 5 cm in diameter, when performed
by experienced surgeons [6–8]. Having said that, caution should be
taken when considering laparoscopic excision of locally advanced
lesions, where the need for major gastrectomy with or without
‘en bloc’ resection of neighbouring organ might be necessary. In
those circumstances it would be more reasonable to favour a con-
ventional open approach that could increase the probability of
complete R0 resection.
2. Cases presentation
We present the two cases of locally advanced gastric GISTs
who did beneﬁt from a 2-stages approach and where delayed
laparoscopic R0 resection could be successfully achieved, without
complication. Case one, at the time an 80 years old female patient
classiﬁed ASA class III with signiﬁcant cardiopulmonary disease
http://dx.doi.org/10.1016/j.ijscr.2015.01.045
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Pre-treatment CT imaging showing (arrows) a large heterogeneous mass arising from the greater curvature of the stomach (S).
Fig. 2. Repeat CT-scan demonstrating a signiﬁcant reduction of the gastric GIST following 6-month neoadjuvant treatment of Imatimib (S: stomach).
Fig. 3. (A) Laparoscopic view of ‘downgraded’ gastric GIST; (B) Laparoscopic stapling of gastric wall with adequate tumour margin; (C) Control of stapled line for haemostasis;
(D) Fully mobilised specimen placed in Endocatch extraction bag.
was investigated for anaemia. Abdominal CT-scan revealed a large
heterogeneous gastric mass measuring 13×13.5 cm, arising from
the greater curvature (Fig. 1) and with classical features of GIST
on endoscopic ultrasound (EUS). There was no evidence of distant
metastases on positron emission tomography (PET) scan and ﬁne
needle aspiration (FNA) biopsy of the lesion conﬁrmed the diag-
nosis. She received neoadjuvant imatimib 400mg per day, as a
single daily dosing for a total of 6 months and a signiﬁcant 70%
reduction of the mass was achieved as conﬁrmed on repeat CT-
scan imaging conﬁrmed (Fig. 2). The patient eventually underwent
laparoscopic wedge excision of the gastric wall encompassing the
residual GIST (Fig. 3). Although she had an uncomplicated post-
operative recovery the patient was discharged home 4 weeks later
as she required signiﬁcant physio mobilisation before being safely
discharged home. Histopathology results demonstrated an excel-
lent response to imatimib with almost complete tumour necrosis
and excision was complete (R0). Imatimib was reintroduced at one
month following her surgery, but was interrupted 6 months later
due to undesired side effects, mainly ﬂuid retention, nausea and
loss of appetite. She is today over 5 years post surgery with still
no evidence of local recurrence or distant metastases on repeat
imaging.
Case two, a 50 years old male patient when he was diagnosed
with a locally advanced non-metastatic 14.5×11.4 cm gastric GIST
abutting (loss of fat plane) the transverse colon. Unrelated, he
also had a large cervical lump occupying most of his right thy-
roid lobe and corresponding to a benign follicular lesion on FNA.
Other relevant problem included presence of central obesity and
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Fig. 4. (A) Laparoscopic view of residual gastric GIST partially wrapped in greater omentum; (B+C) Laparoscopic stapling of the gastric greater curvature; (D) Final control
of haemostasis before tumour retrieval.
a 30 pack-years smoking history. The patient received a 6-month
neoadjuvant treatment of imatimib 400mg single daily dose lead-
ing to partial tumour response (around 50%) as demonstrated on
progressive CT-scan imaging, but showing clear evidence of central
necrosis of the GIST. Incidentally, towards the end of his med-
ical treatment he was found to have a left testicular mass that
was replacing most of his testis on US. Tumour markers were all
negative and there was no evidence of loco-regional or distant
metastases on CT-scan. The patient underwent elective laparo-
scopic excision of the gastric GIST including partial wedge excision
of the greater curvature (Fig. 4), aswell as radical left orchidectomy.
‘En-bloc’ colonic resection was unnecessary as the transverse colon
and its mesentery were free of tumour, with clear margins (R0) on
histopathology. The testicular lesion corresponded to a 4 cm semi-
noma conﬁned to the testis and the surgical margins where also
free of tumour (pT1N0M0). The patient went home on the fourth
post-operative day and subsequently received a single dose of adju-
vant carboplatin forhis seminoma. Imatinibwasalso recommenced
following his surgery for a total of 20months. Of interest, he under-
went right thyroid lobectomy four months following his initial
laparoscopic procedure andwas diagnosed threemonths laterwith
ametastatic seminoma, forwhichhe received three supplementary
cycles of second-line chemotherapy. Thepatient is currently still on
complete remission fromhis gastric GIST andmetastatic seminoma
3 1/2 years later.
3. Discussion
Surgery is the only potentially curative option for gastric GISTs.
Unfortunately, a small proportion of them are locally advanced
measuring >10 cm in size or borderline resectable at initial diagno-
sis, meaning that ‘en bloc’ removal of neighbouring organ might be
necessary to obtain R0 tumour resection. In those situations, min-
imally invasive laparoscopic approach is generally unsuitable and
conventional open surgery is preferred, which is unfortunate espe-
cially in high-risk patients where complication rates are expected
to be higher. Those two cases are good illustrations of large gastric
GISTs successfully treated laparoscopically following neoadjuvant
chemotherapy, while initially unfavourable for such minimally
invasive approach.
Indeed, while still controversial the currently available KIT-
selective tyrosine kinase inhibitor, imatinib (Glivec, formerly
known as STI571, Novartis Pharma AG, Basel, Switzerland) may
be considered as a ﬁrst line of treatment in order to achieve
substantial tumour chemoreduction and improve success rate
of delayed curative-intent surgery, as well as overall survival
[9]. One can extrapolate that tumour down-staging of poten-
tially excisable locally advanced GIST lesions, using neoadjuvant
imatinib-based chemotherapy may ultimately allow reconsidera-
tion to a minimally invasive approach [7,10]. An appealing concept
that unfortunately will necessitate a large randomized multicentre
study with long-term follow up to prove its validity over conven-
tional open surgery. In themean time, only anecdotal observational
case series may offer a partial answer.
4. Conclusion
In summary, patientswith locally advancednon-metastatic gas-
tric GISTs should be offered ﬁrst-line neoadjuvant imatinib-based
cytoreductive chemotherapy as an alternative to radical debulking
surgery, as a substantial proportion of them will experience sig-
niﬁcant tumour shrinkage and therefore eventually beneﬁt from a
much less invasive laparoscopic approach.
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